Chartis® System

The Chartis System is a proprietary pulmonary assessment tool that enables physicians to identify those patients likely to respond to the Pulmonx Zephyr valves with a high degree of confidence.

The Chartis System provides precise flow and pressure readings for specific lobes in the lungs to assess collateral ventilation. Clinical studies have shown that patients with low to no collateral ventilation respond best to Zephyr valve therapy.

Chartis is an excellent idea for helping us find the right patient population.

Dr. Pallav Shah,
MD – Royal Brompton & Harefield London – United Kingdom

The introduction of Chartis has been the most important milestone in patient selection when it comes to endoscopic valve treatment.

Ass. Prof. Arschang Valipour,
MD, PhD, FCCP – Ludwig Boltzmann Institute Vienna – Austria

 

Using the Chartis System in combination with the StratX Lung Analysis Platform, physicians can correctly identify Zephyr valve responders in approximately 90%1 of cases.

 

How it works

The Chartis balloon catheter is inserted through a bronchoscope to the target airway, and the balloon is inflated to block flow to the target region.

The system calculates airway resistance and measures CV in isolated lobes in the lung. The Chartis console displays expiratory air flow (orange), pressure (blue), and resistance measurements.

Collateral ventilation can limit the effectiveness of endobronchial LVR therapy1,2

Using the Chartis System to accurately assess collateral ventilation (CV) within the targeted treatment area, physicians can identify which patients are appropriate for the Zephyr valve therapy.

Expiratory airflow persists over time, indicating the presence of collateral airflow from adjacent lung compartments.

Expiratory airflow in the lung compartment is reduced over several breathing cycles, indicating little to no collateral airflow from adjacent lung compartments.

1 Aljuri N, Freitag L. Validation and pilot clinical study of a new bronchoscopic method to measure collateral ventilation prior to endobronchial lung volume reduction. J Appl Physiol. 2009;106:774-783.
Fessler HE. Collateral damage assessment for endobronchial lung volume reduction. J Appl Physiol. 2009;106:755-756.

Chartis System

Item number Description
CHR-CO‌-300 * Chartis Pulmonary Assessment System – Console
CHR-CO‌-200‌ ** Chartis Pulmonary Assessment System – Console
CHR-CO‌-100 Chartis Pulmonary Assessment System – Console
CHR-CA‌-12.0 Chartis Pulmonary Assessment System – Catheter
CHR-CA‌-12.0-XL Chartis Pulmonary Assessment System – Catheter XL

Note: The Chartis System consists of a disposable balloon catheter and console.
*,** not available on all markets.

References

  1. Koster TD, et al. Predicting lung volume reduction after endobronchial valve therapy is maximized using a combination of diagnostic tools. Respiration Respiration DOI: 10.1159/000448849 – published August 31, 2016
HEALTHCARE PROFESSIONAL USE ONLY

Complications of the Zephyr Endobronchial Valve treatment can include but are not limited to pneumothorax, worsening of COPD symptoms, haemoptysis, pneumonia, dyspnoea and, in rare cases, death.